{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:28:43Z","timestamp":1770337723434,"version":"3.49.0"},"reference-count":68,"publisher":"Informa UK Limited","issue":"8","funder":[{"name":"report"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2022,8,3]]},"DOI":"10.1080\/14737140.2022.2093191","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T07:25:44Z","timestamp":1655796344000},"page":"795-803","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Polatuzumab vedotin in relapsed \/ refractory aggressive B-cell lymphoma"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1903-9170","authenticated-orcid":false,"given":"Gaurav","family":"Varma","sequence":"first","affiliation":[{"name":"NYU Grossman School of Medicine","place":["New York, USA"]},{"name":"NYU Langone Health","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Wang","sequence":"additional","affiliation":[{"name":"NYU Grossman School of Medicine","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Diefenbach","sequence":"additional","affiliation":[{"name":"NYU Grossman School of Medicine","place":["New York, USA"]},{"name":"NYU Langone Health","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"e_1_3_4_3_1","unstructured":"Campo E Harris NL Jaffe ES et al. WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Press."},{"key":"e_1_3_4_4_1","unstructured":"NCCN. B-Cell Lymphomas (Version 1.2022)."},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70002-0"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.089"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-017-0535-0"},{"issue":"19","key":"e_1_3_4_16_1","first-page":"2634","article-title":"Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"137","author":"Hamadani M","year":"2021","unstructured":"Hamadani M, Radford J, Carlo-Stella C, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma. Blood J Am Soc Hematol. 2021;137(19):2634\u20132645.","journal-title":"Blood J Am Soc Hematol"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/08820130500496878"},{"issue":"5","key":"e_1_3_4_18_1","first-page":"413","article-title":"Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders","volume":"84","author":"Cabezudo E","year":"1999","unstructured":"Cabezudo E, Carrara P, Morilla R, et al. Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders. Haematologica. 1999;84(5):413\u2013418.","journal-title":"Haematologica"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.48"},{"issue":"13","key":"e_1_3_4_20_1","first-page":"2721","article-title":"Therapeutic potential of an anti-CD79b antibody\u2013drug conjugate, anti\u2013CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma","volume":"114","author":"Dornan D","year":"2009","unstructured":"Dornan D, Bennett F, Chen Y, et al. Therapeutic potential of an anti-CD79b antibody\u2013drug conjugate, anti\u2013CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood J Am Soc Hematol. 2009;114(13):2721\u20132729.","journal-title":"Blood J Am Soc Hematol"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)44880-0"},{"key":"e_1_3_4_22_1","doi-asserted-by":"crossref","unstructured":"Pettit G. The dolastatins. 1997;Fortschritte der Chemie organischer Naturstoffe Progress in the Chemistry of Organic Natural Products. 70:1\u201379.","DOI":"10.1007\/978-3-7091-6551-5_1"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.6.483"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70128-2"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30026-2"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15232"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.622.622"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.7252"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.5203"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1879-x"},{"key":"e_1_3_4_31_1","unstructured":"Genentech Inc. POLIVY\u2122 (polatuzumab vedotin-piiq) [package insert]. U.S. Food and drug administration website. [Revised Jun 2019. cited 2019. cited Mar 31 2022 Jun 2019. cited Mar 31]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761121s000lbl.pdf"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005794"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00900-7"},{"key":"e_1_3_4_35_1","unstructured":"Celegene Corporation. REVLIMID\u00ae (lenalidomide) [package insert]. U.S. Food and Drug Administration website. [Revised Aug 2021. cited 2021. cited Mar 31 2022 Aug 2021. cited Mar 31]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/021880Orig1s064lblrpl.pdf"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12708"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.119"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.66"},{"issue":"21","key":"e_1_3_4_39_1","first-page":"4713","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay AG","year":"2009","unstructured":"Ramsay AG, Clear AJ, Kelly G, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood J Am Soc Hematol. 2009;114(21):4713\u20134720.","journal-title":"Blood J Am Soc Hematol"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0577"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06841.x"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4405"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3429"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq626"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.95"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.02.001"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7512"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00311-2"},{"key":"e_1_3_4_49_1","unstructured":"AbbVie Inc. VENCLEXTA\u00ae (venetoclax) [package insert]. U.S. Food and Drug Administration website. [Revised Oct 2021. cited 2021. cited Mar 31 2022 Oct 2021. cited Mar 31]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/208573s026lbl.pdf"},{"key":"e_1_3_4_50_1","doi-asserted-by":"crossref","unstructured":"Amin DN Bannerji R Mali RS et al. Abstract CT133: targeting BCL-2 and MCL-1 overcomes treatment resistance in relapsed and refractory non-Hodgkin lymphoma: pre-clinical rationale and results from an open-label phase 1b study. (AACR); 2020.","DOI":"10.1158\/1538-7445.AM2020-CT133"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136361"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2437_126"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.233189"},{"issue":"1","key":"e_1_3_4_54_1","first-page":"1","article-title":"Anti-CD20\u2013atezolizumab\u2013polatuzumab vedotin in relapsed\/refractory follicular and diffuse large B-cell lymphoma","volume":"148","author":"Topp MS","year":"2022","unstructured":"Topp MS, Eradat H, Florsch\u00fctz A, et al. Anti-CD20\u2013atezolizumab\u2013polatuzumab vedotin in relapsed\/refractory follicular and diffuse large B-cell lymphoma. J Cancer Res Clin Oncol. 2022;148(1):1\u20137.","journal-title":"J Cancer Res Clin Oncol"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0028-1"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123742"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136044"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136659"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00889-8"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(21)01892-9"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148359"},{"key":"e_1_3_4_62_1","unstructured":"ADC Therapeutics SA. ZYNLONTA\u2122 (loncastuximab tesirine-lpyl) [package insert]. U.S. Food and Drug Administration website. [Revised Apr 2021. cited 2021. cited Mar 31 2022 Apr 2021. cited Mar 31]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761196s000lbl.pdf"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146800"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.12.013"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1824069"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004155"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005953"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13784"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2842"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2022.2093191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:39:43Z","timestamp":1770291583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2022.2093191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":68,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,3]]}},"alternative-id":["10.1080\/14737140.2022.2093191"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2022.2093191","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-04-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}